Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

L-Carnitine and Reduced C-Reactive Protein Levels

Research synthesisHigh evidenceModerate effect6 studies · 5 beneficial · 1 neutral · 0 harmful

Across 6 studies, 5 reported beneficial effects of L-carnitine supplementation on reducing C-reactive protein (CRP) levels, with effect sizes ranging from small to moderate. The predominant effect size among beneficial studies was moderate, supported by a large meta-analysis (n=3255) showing significant reductions (p<0.001). Median study duration was 46 days, and the most studied doses were 2–3 g/day in clinical populations such as sepsis, migraine, and NAFLD patients.

  • Effective dose range: 2–3 g/day
  • Studied populations: adults with metabolic or inflammatory conditions (e.g., migraine, sepsis, NAFLD, COVID-19)

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). One neutral study (2 g/day, 16 weeks in NAFLD patients) reported no effect on CRP, suggesting possible dose- or population-specific factors. Most studies were short-term (5–84 days), and long-term effects remain unclear.

Generated Jul 12, 2026
Doses used in studies
  • g/day: 2–3 (median 2.5, IQR 2.25–2.75) — 2 studies
  • mg/day: 500–3,000 (median 1,750, IQR 1,125–2,375) — 2 studies
Time to effect
Median: 6.5 weeks · IQR 7 days–3 months · Range 5 days–3.7 months — Reported in 4 of 6 studies
Safety in these studies
6 of 6 papers
Back to top